Erratum: Modelling mutational landscapes of human cancers in vitro (Scientific Reports (2017) 4 (4482) DOI: 10.1038/srep04482);Modelling mutational landscapes of human cancers in vitro

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Olivier, Magali ^a   Weninger, Annette ^b   Ardin, Maude ^a   Huskova, Hana ^a   Castells, Xavier ^a   Vallée, Maxime P ^a   McKay, James ^a   Nedelko, Tatiana ^b   Muehlbauer, Karl Rudolf ^b   Marusawa, Hiroyuki ^c   Alexander, John ^d   Hazelwood, Lee ^d   Byrnes, Graham ^a   Hollstein, Monica ^b,d   Zavadil, Jiri ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BIOLOGY; EXOME; GENETIC ASSOCIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; IN VITRO STUDY; MOUSE; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PROCEDURES; TRANSFORMED CELL LINE;

ANIMALS; CELL LINE, TRANSFORMED; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; EXOME; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN VITRO TECHNIQUES; MICE; MUTATION; NEOPLASMS;

EID: 84905382541     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep40898     Document Type: Erratum

References (51)

1. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
2. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
3. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
4. Hollstein, M., McCann, J., Angelosanto, F. A. & Nichols, W. W. Short-term tests for carcinogens and mutagens. Mutat. Res. 65, 133-226 (1979).
5. Miller, J. H. Carcinogens induce targeted mutations in Escherichia coli. Cell 31, 5-7 (1982).
6. Hahn,W. C. & Weinberg, R. A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2, 331-341 (2002).
7. Collado, M. & Serrano, M. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 10, 51-57 (2010).
8. Fridman, A. L. & Tainsky, M. A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 27, 5975-5987 (2008).
9. Odell, A., Askham, J., Whibley, C. & Hollstein, M. How to become immortal: let MEFs count the ways. Aging (Albany. NY) 2, 160-165 (2010).
10. Liu, Z. et al. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. U. S. A 101, 2963-2968 (2004).
11. Liu, Z. et al. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res. 65, 2583-2587 (2005).
12. vom Brocke, J., Schmeiser, H. H., Reinbold, M. & Hollstein, M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27, 2141-2147 (2006).
13. Schmitz, K. M. & Petersen-Mahrt, S. K. AIDing the immune system-DIAbolic in cancer. Semin. Immunol. 24, 241-245 (2012).
14. Hoang, M. L. et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 5, 197ra102 (2013).
15. Poon, S. L. et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 5, 197ra101 (2013).
16. Yoshikawa, K. et al. AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 296, 2033-2036 (2002).
17. Whibley, C. et al.Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J Biol. Chem. 285, 11326-11335 (2010).
18. Chen, C. H. et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. U. S. A 109, 8241-8246 (2012).
19. Moriya, M. et al. TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int. J. Cancer 129, 1532-1536 (2011).
20. Sidorenko, V. S. et al. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res. 40, 2494-2505 (2012).
21. Bransteitter, R., Pham, P., Calabrese, P.&Goodman,M. F. Biochemical analysis of hypermutational targeting by wild type and mutant activation-induced cytidine deaminase. J. Biol. Chem. 279, 51612-51621 (2004).
22. Pham, P., Bransteitter, R., Petruska, J. & Goodman, M. F. Processive AIDcatalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 424, 103-107 (2003).
23. Duncan, B. K.& Miller, J. H. Mutagenic deamination of cytosine residues in DNA. Nature 287, 560-561 (1980).
24. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013).
25. Plass, C. et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 14, 765-780 (2013).
26. Timp,W. & Feinberg, A. P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13, 497-510 (2013).
27. Chan, H. M., Narita, M., Lowe, S. W. & Livingston, D. M. The p400 E1Aassociated protein is a novel component of the p53 - .p21 senescence pathway. Genes Dev. 19, 196-201 (2005).
28. Schmeiser, H. H. et al. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res. 50, 5464-5469 (1990).
29. Schmeiser, H. H., Scherf, H. R. &Wiessler,M.Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett. 59, 139-143 (1991).
30. Wang, Y. et al. ACB-PCR measurement of H-ras codon 61 CAA - .CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues. Environ. Mol. Mutagen. 53, 495-504 (2012).
31. Lundberg, A. S., Hahn, W. C., Gupta, P. & Weinberg, R. A. Genes involved in senescence and immortalization. Curr. Opin. Cell Biol. 12, 705-709 (2000).
32. Hollstein, M., Moriya, M., Grollman, A. P. & Olivier, M. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat. Res. 753, 41-49 (2013).
33. Lindahl, T. Instability and decay of the primary structure of DNA. Nature 362, 709-715 (1993).
34. Burns, M. B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366-370 (2013).
35. Burns, M. B., Temiz, N. A.&Harris, R. S. Evidence for APOBEC3Bmutagenesis in multiple human cancers. Nat. Genet. 45, 977-983 (2013).
36. Chiba, T., Marusawa, H. & Ushijima, T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 143, 550-563 (2012).
37. Shimizu, T., Marusawa, H., Endo, Y. & Chiba, T. Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci. 103, 1201-1206 (2012).
38. Maitra, A. et al. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nat. Commun. 4, 2873 (2013).
39. Kino, K. & Sugiyama, H. GC - .CG transversion mutation might be caused by 8- oxoguanine oxidation product. Nucleic Acids Symp. Ser. 139-140 (2000).
40. Paz-Elizur, T. et al. DNA repair activity for oxidative damage and risk of lung cancer. J. Natl. Cancer Inst. 95, 1312-1319 (2003).
41. Tommasi, S. et al.Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids Res. 41, 182-195 (2013).
42. Harvey, D. M. &Levine, A. J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5, 2375-2385 (1991).
43. Kamijo, T. et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U. S. A 95, 8292-8297 (1998).
44. Todaro, G. J. &Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17, 299-313 (1963).
45. Luo, J. L. et al. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20, 320-328 (2001).
46. Reinbold, M. et al. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 27, 2788-2794 (2008).
47. Okazaki, I. M. et al. Constitutive expression of AID leads to tumorigenesis. J. Exp. Med. 197, 1173-1181 (2003).
48. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
49. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014).
50. Yost, S. E. et al. High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. PLoS. One 8, e56185 (2013).
51. Brunet, J. P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. U. S. A 101, 4164-4169 (2004).